CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
TSX:CPH - CA17253X1050 - Common Stock
15.93 CAD
+0.29 (+1.85%)
We assign a fundamental rating of 6 out of 10 to CPH. CPH was compared to 34 industry peers in the Pharmaceuticals industry. CPH scores excellent on profitability, but there are some minor concerns on its financial health. CPH is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year CPH was profitable.
In the past year CPH had a positive cash flow from operations.
Each year in the past 5 years CPH has been profitable.
Each year in the past 5 years CPH had a positive operating cash flow.
1.2 Ratios
CPH has a Return On Assets of 7.97%. This is amongst the best in the industry. CPH outperforms 94.12% of its industry peers.
CPH's Return On Equity of 11.10% is amongst the best of the industry. CPH outperforms 88.24% of its industry peers.
CPH's Return On Invested Capital of 5.17% is amongst the best of the industry. CPH outperforms 85.29% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CPH is in line with the industry average of 7.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 11.1% | ||
| ROIC | 5.17% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
The Profit Margin of CPH (25.52%) is better than 100.00% of its industry peers.
In the last couple of years the Profit Margin of CPH has grown nicely.
CPH's Operating Margin of 20.32% is amongst the best of the industry. CPH outperforms 88.24% of its industry peers.
In the last couple of years the Operating Margin of CPH has declined.
CPH has a Gross Margin of 73.79%. This is amongst the best in the industry. CPH outperforms 94.12% of its industry peers.
CPH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.32% | ||
| PM (TTM) | 25.52% | ||
| GM | 73.79% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CPH is destroying value.
The number of shares outstanding for CPH has been increased compared to 1 year ago.
Compared to 5 years ago, CPH has less shares outstanding
The debt/assets ratio for CPH is higher compared to a year ago.
2.2 Solvency
CPH has an Altman-Z score of 5.43. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
CPH has a Altman-Z score of 5.43. This is amongst the best in the industry. CPH outperforms 94.12% of its industry peers.
A Debt/Equity ratio of 0.23 indicates that CPH is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.23, CPH perfoms like the industry average, outperforming 52.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.43 |
ROIC/WACC0.57
WACC9.14%
2.3 Liquidity
CPH has a Current Ratio of 1.72. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
CPH has a Current ratio of 1.72. This is comparable to the rest of the industry: CPH outperforms 52.94% of its industry peers.
CPH has a Quick Ratio of 1.41. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
CPH's Quick ratio of 1.41 is in line compared to the rest of the industry. CPH outperforms 52.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 |
3. Growth
3.1 Past
The earnings per share for CPH have decreased strongly by -48.31% in the last year.
Measured over the past years, CPH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.47% on average per year.
Looking at the last year, CPH shows a very strong growth in Revenue. The Revenue has grown by 114.76%.
CPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.25% yearly.
EPS 1Y (TTM)-48.31%
EPS 3Y13.23%
EPS 5Y12.47%
EPS Q2Q%83.33%
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
3.2 Future
The Earnings Per Share is expected to grow by 14.85% on average over the next years. This is quite good.
Based on estimates for the next years, CPH will show a very strong growth in Revenue. The Revenue will grow by 21.67% on average per year.
EPS Next Y105.37%
EPS Next 2Y21.71%
EPS Next 3Y14.85%
EPS Next 5YN/A
Revenue Next Year49.11%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 25.29 indicates a quite expensive valuation of CPH.
Based on the Price/Earnings ratio, CPH is valued cheaply inside the industry as 82.35% of the companies are valued more expensively.
CPH's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.08.
Based on the Price/Forward Earnings ratio of 17.37, the valuation of CPH can be described as rather expensive.
CPH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CPH is cheaper than 79.41% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of CPH to the average of the S&P500 Index (22.72), we can say CPH is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.29 | ||
| Fwd PE | 17.37 |
4.2 Price Multiples
61.76% of the companies in the same industry are more expensive than CPH, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 18.09 |
4.3 Compensation for Growth
CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPH may justify a higher PE ratio.
A more expensive valuation may be justified as CPH's earnings are expected to grow with 14.85% in the coming years.
PEG (NY)0.24
PEG (5Y)2.03
EPS Next 2Y21.71%
EPS Next 3Y14.85%
5. Dividend
5.1 Amount
CPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CPH (8/29/2025, 7:00:00 PM)
15.93
+0.29 (+1.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.35%
Inst Owner ChangeN/A
Ins Owners4.67%
Ins Owner ChangeN/A
Market Cap404.46M
Analysts77.78
Price Target17.87 (12.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.48%
Min EPS beat(2)-7.18%
Max EPS beat(2)36.14%
EPS beat(4)2
Avg EPS beat(4)-14.13%
Min EPS beat(4)-92.76%
Max EPS beat(4)36.14%
EPS beat(8)6
Avg EPS beat(8)67.23%
EPS beat(12)10
Avg EPS beat(12)112.56%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.9%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)2.48%
Revenue beat(4)3
Avg Revenue beat(4)31.13%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)115.89%
Revenue beat(8)5
Avg Revenue beat(8)22.37%
Revenue beat(12)5
Avg Revenue beat(12)11.03%
Revenue beat(16)5
Avg Revenue beat(16)5.52%
PT rev (1m)9.36%
PT rev (3m)4.78%
EPS NQ rev (1m)-16.67%
EPS NQ rev (3m)N/A
EPS NY rev (1m)46.4%
EPS NY rev (3m)46.4%
Revenue NQ rev (1m)1.88%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.47%
Revenue NY rev (3m)-1.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.29 | ||
| Fwd PE | 17.37 | ||
| P/S | 6.18 | ||
| P/FCF | N/A | ||
| P/OCF | 13.92 | ||
| P/B | 2.69 | ||
| P/tB | 17.6 | ||
| EV/EBITDA | 18.09 |
EPS(TTM)0.63
EY3.95%
EPS(NY)0.92
Fwd EY5.76%
FCF(TTM)-3.19
FCFYN/A
OCF(TTM)1.14
OCFY7.19%
SpS2.58
BVpS5.93
TBVpS0.91
PEG (NY)0.24
PEG (5Y)2.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 11.1% | ||
| ROCE | 7.18% | ||
| ROIC | 5.17% | ||
| ROICexc | 5.65% | ||
| ROICexgc | 22.78% | ||
| OM | 20.32% | ||
| PM (TTM) | 25.52% | ||
| GM | 73.79% | ||
| FCFM | N/A |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.51 | ||
| Cap/Depr | 1132.75% | ||
| Cap/Sales | 168.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 126.25% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 | ||
| Altman-Z | 5.43 |
F-Score5
WACC9.14%
ROIC/WACC0.57
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y13.23%
EPS 5Y12.47%
EPS Q2Q%83.33%
EPS Next Y105.37%
EPS Next 2Y21.71%
EPS Next 3Y14.85%
EPS Next 5YN/A
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
Revenue Next Year49.11%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
EBIT growth 1Y-12.36%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year116.14%
EBIT Next 3Y39.51%
EBIT Next 5YN/A
FCF growth 1Y-558.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.27%
OCF growth 3Y12.28%
OCF growth 5Y19.77%